Description In vitro In vivo
ChemicalBook > CAS DataBase List > Linsitinib

Linsitinib

Description In vitro In vivo
Product Name
Linsitinib
CAS No.
867160-71-2
Chemical Name
Linsitinib
Synonyms
OSI-906;CS-190;OSI 906AA;Linsitinib;OSI 906;OSI906;Linsitinib(OSI906);OSI-906 Linsitinib;Linsitinib USP/EP/BP;Linsitinib, Free Base;LINSITINIB;OSI 906; OSI906
CBNumber
CB62501004
Molecular Formula
C26H23N5O
Formula Weight
421.49
MOL File
867160-71-2.mol
More
Less

Linsitinib Property

Melting point:
>175°C (dec.)
Density 
1.39
storage temp. 
-20°C
solubility 
Soluble in DMSO (up to 30 mg/ml)
form 
solid
pka
14.84±0.40(Predicted)
color 
Yellow
Stability:
Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 2 months.
More
Less

Hazard and Precautionary Statements (GHS)

Symbol(GHS)
Signal word
Warning
More
Less

N-Bromosuccinimide Price

Cayman Chemical
Product number
17708
Product name
Linsitinib
Purity
≥98%
Packaging
1mg
Price
$40
Updated
2024/03/01
Cayman Chemical
Product number
17708
Product name
Linsitinib
Purity
≥98%
Packaging
5mg
Price
$119
Updated
2024/03/01
Cayman Chemical
Product number
17708
Product name
Linsitinib
Purity
≥98%
Packaging
10mg
Price
$218
Updated
2024/03/01
Usbiological
Product number
015629
Product name
Linsitinib
Packaging
5mg
Price
$245
Updated
2021/12/16
TRC
Product number
L469020
Product name
Linsitinib
Packaging
100mg
Price
$990
Updated
2021/12/16
More
Less

Linsitinib Chemical Properties,Usage,Production

Description

Linsitinib (OSI-906) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.

In vitro

OSI-906 inhibits IGF-1R autophosphorylation and activation of the downstream signaling proteins Akt, ERK1/2 and S6 kinase with IC50 of 0.028 to 0.13 μM. OSI-906 enables an intermediate conformation of the target protein through interactions with the C-helix. OSI-906 displays favorable metabolic stability in liver microsomes. OSI-906 fully inhibits both IR and IGF-1R phosphorylation at a concentration of 1 μM. OSI-906 inhibits proliferation of several tumor cell lines including non-small-cell lung cancer and colorectal cancer (CRC) tumor cell line with EC50 of 0.021 to 0.810 μM.

In vivo

OSI-906 inhibits tumor growth in an IGF-1R-driven xenograft mouse model, with 100% TGI and 55% regression at a dose of 75 mg/kg and 60% TGI and no regression at a dose of 25 mg/kg. OSI-906 administration induces different elimination half-lives of itself in dog, rat and mice, the elimination half-lives are 1.18 hours, 2.64 hours and 2.14 hours, respectively. OSI-906 administration at different single dose once-daily in femal Sprague-Dawley rat and femal CD-1 mouse reveal that the Vmax is not dose-proportional to OSI-906 dose. OSI-906 elevates the blood glucose levels at a dose of 25 mg/kg after 12 days administration. OSI-906 administration at a single dose of 75 mg/kg in IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model achieve maximal inhibition of IGF-1R phosphorylation (80%) between 4 and 24 hours with plasma drug concentrations of 26.6-4.77 μM. OSI-906 administered as a single dose of at 60 mg/kg in NCI-H292 xenografts mice inhibits uptake of glucose at 2, 4, and 24 hours post-treatment in vivo. OSI-906 inhibits the growth of tumors in NCI-H292 xenograft mouse model.

Description

The binding of insulin-like growth factor 1 (IGF-1) to the IGF-1 receptor (IGF-1R) promotes cell growth while inhibiting apoptotic pathways. Overexpression of IGF-1R is found in certain solid tumors and hematologic neoplasias. However, insulin receptor (InsR) signaling can compensate for IGF-1R inhibition. Linsitinib is a dual inhibitor of IGF-1R and InsR kinases (IC50s = 35 and 75 nM, respectively). It also inhibits InsR-related receptor (IC50 = 75 nM) but is without effect (IC50 > 10 μM) against a large panel of other kinases. Linsitinib inhibits proliferation of a variety of tumor cell lines in vitro and has antitumor efficacy in an IGF-1R-driven xenograft mouse model when administered orally. A rapid, non-invasive method to predict the pharmacodynamic response to linsitinib has been reported.

Uses

Linsitinib is a small-molecule dual insulin-like growth factor-1 receptor (IGF-IR) and insulin receptor (IR) kinase inhibitor. IGF-I receptor (IGF-IR) has been implicated in the promotion of tumorigenesis, metastasis and resistance to cancer therapies and thus Linsitinib may be a useful anticancer agent. Potent IGF-1R inhibitor.

Definition

ChEBI: 3-[8-amino-1-(2-phenyl-7-quinolinyl)-3-imidazo[1,5-a]pyrazinyl]-1-methyl-1-cyclobutanol is a member of quinolines and a member of cyclobutanes.

target

IGF-1R

storage

Store at -20°C

References

1) Mulvihill?et al.?(2009),?Discovery of OSI-906: a selective and orally efficacious inhibitor of the IGF-1 receptor and insulin receptor; Future Med. Chem.?1?1153 2) Bendell?et al.?(2015),?A phase Ib study of linsitinib (OSI-906), a dual inhibitor of IGF-1R and IR tyrosine kinase, in combination with everolimus as treatment for patients with refractory metastatic colorectal cancer; Invest. New Drugs?33?187 3) Pivonello?et al.?(2016),?The dual targeting of insulin and insulin-like growth factor 1 receptor enhances the mTOR inhibitor-mediated antitumor efficacy in hepatocellular carcinoma?; Oncotarget?7?9718 4) Lee?et al.?(2016),?Inhibition of IGF1R signaling abrogates resistance to afatinib (BIBW2992) in EGFR T790M mutant lung cancer cells; Mol. Carcinog.?55?991 5) Macaulay?et al.?(2016),?Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors; Clin. Cancer Res.?22?2897 6) De Lint?et al.?(2016),?Sensitizing Triple-Negative Breast Cancer to PI3K Inhibition by Cotargeting IGF1R; Mol. Cancer Ther.?15?1545

Linsitinib Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

Linsitinib Suppliers

China 123 India 3 United Kingdom 1 United States 22 Global 149
Shanghai XingMo Biotechnology Co., Ltd.
Tel
+86 13524779951; 13524779951
Fax
QQ: 2075692521
Email
2075692521@qq.com
Country
China
ProdList
309
Advantage
55
Shanghai Boyle Chemical Co., Ltd.
Tel
Fax
86-21-57758967
Email
sales@boylechem.com
Country
China
ProdList
2922
Advantage
55
J & K SCIENTIFIC LTD.
Tel
010-82848833 400-666-7788
Fax
86-10-82849933
Email
jkinfo@jkchemical.com
Country
China
ProdList
94657
Advantage
76
Chembest Research Laboratories Limited
Tel
+86-21-20908456
Fax
021-58180499
Email
sales@BioChemBest.com
Country
China
ProdList
6005
Advantage
61
Jia Xing Isenchem Co.,Ltd
Tel
0573-85285100 18627885956
Fax
0573-85285100
Email
isenchem@163.com
Country
China
ProdList
9513
Advantage
66
VDM Biochemicals
Tel
0330-2528181
Fax
0330-2528171
Email
sales@vdmbio.com
Country
United States
ProdList
510
Advantage
64
Chemsky（shanghai）International Co.,Ltd.
Tel
021-50135380
Email
shchemsky@sina.com
Country
China
ProdList
32321
Advantage
50
China DongFan Chemical Co.,LTD
Tel
86-0571-85151182
Fax
86-0571-85151182
Country
China
ProdList
5691
Advantage
66
Jinan Trio PharmaTech Co., Ltd.
Tel
+86 (531) 88811783
Fax
+86 (531) 55696010 QQ 1762738062
Email
sales@trio-pharmatech.com (International market)
Country
China
ProdList
1856
Advantage
62
Dalian Meilun Biotech Co., Ltd.
Tel
0411-62910999 13889544652
Email
meilunui@163.com
Country
China
ProdList
4727
Advantage
58
More
Less

View Lastest Price from Linsitinib manufacturers

Henan Aochuang Chemical Co.,Ltd.
Product
Linsitinib 867160-71-2
Price
US $0.00-0.00/KG
Min. Order
1KG
Purity
98%
Supply Ability
1Ton
Release date
2022-10-13
Career Henan Chemical Co
Product
Linsitinib 867160-71-2
Price
US $6.68/KG
Min. Order
1KG
Purity
97%-99%
Supply Ability
1kg-1000kg
Release date
2020-01-08

867160-71-2, LinsitinibRelated Search:

Geldanamycin LFM-A13 Vorinostat (+)-Camptothecin lifitegrast Linagliptin Y27632 (hydrochloride) MK-2206 2HCl Erlotinib hydrochloride SCH772984 BMS-754807 Olaparib

  • OSI-906
  • cis-3-[8-Amino-1-(2-phenyl-7-quinolinyl)imidazo[1,5-a]pyrazin-3-yl]-1-methylcyclobutanol
  • Linsitinib
  • OSI-906 Linsitinib
  • Cyclobutanol, 3-[8-aMino-1-(2-phenyl-7-quinolinyl)iMidazo[1,5-a]pyrazin-3-yl]-1-Methyl-, cis-
  • OSI 906AA
  • (1S,3r)-3-((S)-8-aMino-1-(2-phenylquinolin-7-yl)-2,3-dihydroiMidazo[1,5-a]pyrazin-3-yl)-1-Methylcyclobutanol
  • (1s,3r)-3-[4-aMino-3-(2-phenylquinolin-7-yl)iMidazo[1,5-a]pyrazin-1-yl]-1-Methylcyclobutan-1-ol
  • Linsitinib, Free Base
  • LINSITINIB;OSI 906; OSI906
  • Linsitinib(OSI906)
  • (1s,3s)-3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl)-1-methylcyclobutanol
  • cis-3-[8-Amino-1-(2-phenyl-7-quinolinyl)imidazo[1,5-a]pyrazin-3-yl]-1-methylcyclobutanol Linsitinib(OSI906)
  • 3-(8-Amino-1-(2-phenylquinolin-7-yl)-2,3-dihydro-imidazo[1,5-a]pyrazin-3-yl)-1-methylcyclobuta
  • CS-190
  • OSI 906;OSI906
  • 3-[8-AMINO-1-(2-PHENYLQUINOLIN-7-YL)IMIDAZO[1,5-A]PYRAZIN-3-YL]-1-METHYLCYCLOBUTAN-1-OL
  • (1s,3s)-3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl)-1-methylcyclobutan-1-ol
  • Linsitinib USP/EP/BP
  • Cis-3-(8-Amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl)-1-methylcyclobutan-1-ol
  • 867160-71-2
  • Tyrosine Kinase Inhibitors
  • Inhibitors
  • Amines
  • Aromatics
  • Heterocycles
  • Intermediates & Fine Chemicals
  • Pharmaceuticals